Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Statements of Operations and Comprehensive Loss

v3.25.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Operating Expenses:    
Research and development $ 1,401,435 $ 2,303,751
Research and development - related parties 567,832 480,777
General and administrative 4,355,462 10,646,417
General and administrative - related parties 46,555
Total Operating Expenses 6,324,729 13,477,500
Loss From Operations (6,324,729) (13,477,500)
Other (Expense) Income:    
Other income 2,822,864 21,074
Interest expense (50,640) (44,828)
Loss on asset impairment (1,526,542) (9,063,000)
Change in fair value of derivative liabilities 58 75,323
Change in fair value of preferred stock liability (1,577,305)
Gain on settlement of liabilities 192,093 204,405
Total other (expense) income, net (139,472) (8,807,026)
Loss Before Income Taxes (6,464,201) (22,284,526)
Income tax benefit 296,024 2,349,414
Net Loss (6,168,177) (19,935,112)
Deemed Dividend (8,011,510)
Net Loss Available to Common Stockholders (14,179,687) (19,935,112)
Other Comprehensive Loss:    
Foreign currency translation adjustments (15,579) (15,816)
Total Comprehensive Loss $ (14,195,266) $ (19,950,928)
Basic and Diluted Net Loss per Common Share    
Basic (in Dollars per share) $ (15.49) $ (52.59)
Diluted (in Dollars per share) $ (15.49) $ (52.59)
Weighted Average Number of Common Shares Outstanding:    
Basic (in Shares) 915,374 379,089
Diluted (in Shares) 915,374 379,089